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Barrett’s esophagus (BE) is the only known precursor to 
esophageal adenocarcinoma (EAC), whose incidence has 
increased sharply in the last 4 decades. The annual conver-
sion rate of BE to cancer is significant, but small. The identifi-
cation of patients at a higher risk of cancer therefore poses a 
clinical conundrum. Currently, endoscopic surveillance is rec-
ommended in BE patients, with the aim of diagnosing either 
dysplasia or cancer at early stages, both of which are curable 
with minimally invasive endoscopic techniques. There is a 
large variation in clinical practice for endoscopic surveillance, 
and dysplasia as a marker of increased risk is affected by 
sampling error and high interobserver variability. Screening 
programs have not yet been formally accepted, mainly due 
to the economic burden that would be generated by upper 
gastrointestinal endoscopy. Screening programs have not yet 
been formally accepted, mainly due to the economic burden 
that would be generated by widespread indication to upper 
gastrointestinal endoscopy. In fact, it is currently difficult to 
formulate an accurate algorithm to confidently target the 
population at risk, based on the known clinical risk factors 
for BE and EAC. This review will focus on the clinical and 
molecular factors that are involved in the development of BE 
and its conversion to cancer and on how increased knowl-
edge in these areas can improve the clinical management of 
the disease. (Gut Liver 2014;8:356-370)
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INTRODUCTION
Barrett’s esophagus (BE) is an acquired condition in which 
a metaplastic columnar lining with intestinal differentiation 
replaces the stratified squamous epithelium in the distal esopha-
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gus. The metaplastic epithelium comprises three different cell 
types: atrophic gastric-fundic-type epithelium containing pari-
etal and chief cells; a transitional-type epithelium with cardiac 
mucous-secreting glands; and specialized columnar epithelium 
with intestinal-type goblet cells.1 While American gastroentero-
logical societies consider the specialized epithelium with goblet 
cells a requirement for the diagnosis of BE,2 British guidelines 
consider the possibility of including BE with gastric metaplasia 
only.3
The true prevalence of BE is still unclear. In recent years Ital-
ian and Swedish researchers were able to show a prevalence of 
1.3% and 1.6%, respectively, although in both studies a selec-
tion bias may have led to an over-estimate.4,5 BE generally de-
velops in the context of chronic gastroesophageal reflux disease 
(GERD) and it is about 10 times more frequent in individuals 
who complain of reflux symptoms.5-7 BE is the only known 
precursor to esophageal adenocarcinoma (EAC), with an annual 
conversion rate of approximately 0.3%.8-10 In recent U.K. statis-
tics, the esophagus was rated as the 7th most common cancer 
site among males and 14th among females. However esopha-
geal malignancy was the fourth most common cause of cancer-
related death in men and sixth in women in this geographical 
area. Although these data related to both of the most common 
histologic types, adenocarcinoma and squamous cell carcinoma 
(SCC), it is known that the overall prognosis of these two types 
of cancer is similar.11 The discrepancy between incidence and 
mortality rates stems from the fact that esophageal cancer is ag-
gressive in nature and relatively asymptomatic at early stages 
leading to a low overall 5-year survival rate (<15%).12,13 There 
is a large geographical variation in the incidence of esophageal 
cancer (Fig. 1A),14 with a higher incidence of SCC in African and 
Asian countries. Notably, the incidence of esophageal adeno-
carcinoma has been worryingly increasing over the last 3 to 4 
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decades in the Western world (Fig. 1B),15,16 where it has become 
the most common esophageal malignancy.17,18 In keeping with 
this, GERD is also increasing in incidence in the Western popu-
lation19,20 and has been found to be the most common gatro-
intestinal (GI) diagnosis in an outpatient setting in the United 
States.21 This epidemiological picture has led to the question 
of whether screening programs for BE are justified.22 Since the 
gold standard for a diagnosis of BE is endoscopy with biopsies, 
this screening method would be too costly and invasive to be 
applied to the general population. All of the most recently pub-
lished guidelines do not recommend screening of the unselected 
population, but do suggest to target the population at higher 
risk of BE.2,3 Here we review the current knowledge on clinical 
and molecular factors associated to the risk of BE and EAC and 
analyse how an improved understanding of this condition can 
influence clinical algorithms for the management of this dis-
ease.
RISK FACTORS FOR BE
There are numerous risk factors for BE and they are generally 
shared with EAC. Gastroesophageal acid reflux is considered 
the most important factor. In a population-based case-control 
study, gastroesophageal reflux was associated with BE and EAC, 
with an odd ratio (OR) of 12.0 (95% confidence interval [CI], 7.64 
to 18.7) and 3.48 (95% CI, 2.25 to 5.41), respectively.23 A recent 
meta-analysis showed that GERD symptoms increased the odds 
of long segment BE by fivefold.24 The prevalence of BE in pa-
tients with GERD varies between 3% and 15% depending on the 
study.6,7,22,23 This large range mostly relates to the stringency of 
criteria used for the selection of patients with reflux disease. 
Obesity is the second strongest risk factor for the develop-
ment of BE and EAC.23,25 Obesity and GERD have synergistic ef-
fects according to a population-based case-control study, which 
demonstrated that obese individuals with symptoms of acid 
reflux had markedly higher risks of BE (OR, 34.4; 95% CI, 6.3 
to 188) than people with reflux alone (OR, 9.3; 95% CI, 1.4 to 
62.2) or obesity alone (OR, 0.7; 95% CI, 0.2 to 2.4).26 The distri-
bution of fat also has a role in determining the risk in that large 
amount of visceral abdominal fat relative to subcutaneous fat is 
associated with a significant increase in the risk of BE.27,28
Smokers and ex-smokers are also at increased risk of EAC.23 
A meta-analysis demonstrated a strong association between 
cigarette smoking and EAC with a dose-response relation to dis-
ease outcome. In addition longer smoking cessation was associ-
ated with a decreased risk of adenocarcinoma.29 However, the 
association of smoking with BE remains controversial according 
to different studies.30,31
Other risk factors include male sex, white race, low vegetables 
intake and high red meat consumption, whereas data have 
showed an inverse correlation with Helicobacter pylori infec-
tion.8,16,32-35
BE has also been shown to occur in familial clusters. Studies 
in different populations of patients with BE and EAC confirmed 
that about 7% of cases are familial.36,37 Juhasz and collabora-
tors38 studied 47 first degree relatives of patients with EAC and 
BE-related high-grade dysplasia from 23 families and confirmed 
BE in 13 relatives (27.7%).
Fig. 1. (A) World age-standardized incidence rates of esophageal cancer per 100,000 population. Estimates derived from Cancer Research UK 
statistics (Ferlay J, et al. GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide).14 (B) Relative change in the incidence of esophageal 
adenocarcinoma (1973 to 2006). With permission from Pohl H, et al. Cancer Epidemiol Biomarkers Prev 2010;19:1468-1470.15
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A genetic background to this disease is supported by recent 
genome-wide association studies (GWAS). A first GWAS re-
port demonstrated that variants at two loci were associated 
with disease risk; chromosome 6p21 (OR, 1.21; 95% CI, 1.13 to 
1.28), within the major histocompatibility complex locus, and 
chromosome 16q24 (OR, 1.14; 95% CI, 1.10 to 1.19), in close 
proximity to FOXF1 gene, which is implicated in esophageal 
development and structure.39 In a second GWAS study Levine 
and coworkers40 compared EAC cases (n=2,390) and individuals 
with BE (n=3,175) with 10,120 controls. Three new association 
loci were identified; 19p13 within CRTC1, whose activation has 
been associated with oncogenic activity, 9q22 within BARX1, 
which encodes a transcription factor involved in esophageal 
specification and 3p14 near the transcription factor FOXP1, 
which regulates esophageal development.
MOLECULAR PATHWAYS RELATED TO BARRETT’S DE-
VELOPMENT AND PROGRESSION TO CANCER
The cell of origin of BE within the esophagus remains a con-
troversial issue. Recent evidence in mice-models showed that BE 
may originate from progenitor cells present within the gastric 
cardia in close proximity with the gastroesophageal junction. 
Two models have been proposed to recapitulate the origin of 
BE. In p63-deficient mice, it was shown that the normal squa-
mous re-epithelisation of the esophagus during embryogenesis 
is impaired and this gives rise to upward migration of embry-
onic columnar remnant cells located at the level of the squa-
mocolumnar junction (SCJ), generating a columnar epithelium 
reminiscent of BE.41 In a different study, Quante and cowork-
ers42 were able to show that mice overexpressing interleukin-
1β have an inflammatory response at the SCJ, which leads to a 
columnar lined esophagus that is molecularly similar to BE. In 
these mice, increased esophageal exposure to bile and acid trig-
gered a sustained inflammatory response that reinforces Bar-
rett’s like carcinogenesis in a Notch-dependent fashion. Overall, 
these mouse models provide support to the theory that BE may 
originates from progenitor cells located at the SCJ and would 
explain why BE is generally in anatomical continuity with the 
cardia epithelium. However, the different anatomy of the mu-
rine esophagus warrant further studies to translate these models 
into the human pathology. An alternative theory is that BE may 
originate through a process of transdifferentiation of squamous 
cells or reprogramming of esophageal stem cell towards a dif-
ferent phenotype. This would likely involve epigenetic repro-
gramming of esophageal cells. In support of this theory is the 
evidence that genes normally involved in differentiation and 
gut axial specification are modulated in BE. Increased expres-
sion of the caudal-related gene CDX2 and CDX1, which are 
normally highly expressed in colon, has been shown in BE and 
related to the acquisition of the intestinal phenotype.43 This gene 
regulation has recently been linked to change in the methyla-
tion status of the promoter44 and associated to the acid/bile in-
duced inflammation through the activation of nuclear factor κB, 
a crucial transcription factor in the inflammatory response.45 In 
addition, acquired deregulation of HOX genes during adulthood 
has been linked to carcinogenesis. We have recently showed 
that three HOXB genes (HOXB5, HOXB6, and HOXB7) are acti-
vated in BE through an epigenetic mechanism involving histone 
posttranslational modifications. Alterations to the HOX gene 
expression in esophageal cells was associated with the induction 
of genes linked to an intestinal-phenotype.46 The cell target of 
the epigenetic reprogramming of differentiation genes remain 
to be established, especially after the recent evidence of lack of 
bona fide stem cells in the human esophagus.47 
Chronic reflux of acid and bile into the esophagus normally 
results in an acute and chronic inflammatory process. In vivo 
and ex vivo exposure of esophageal cells to acid and bile salts 
can induce the production of reactive oxygen species and nitric 
oxide,48,49 which are related to oxidative DNA damage and dou-
ble-strand breaks.50,51 These events have been linked in general 
to carcinogenesis and more recently to the metaplasia, dysplasia 
to cancer sequence in BE.50 In addition, oxidative DNA dam-
age in BE causes telomerase activation and telomere instability, 
which are known to result in mutation of cancer-related genes 
and promotion of cancer.52
Inflammation is also related to recruitment of immune cells. 
Naive T cells, macrophages and dendritic cells are enriched in 
both nondysplastic and dysplastic BE, as well as in EAC.53-55 
These cells could contribute to tumorigenesis through produc-
tion of cytokines, chemokines and growth factors, which are 
released as part of the inflammatory response and can promote 
proliferation and angiogenesis.56
Exposure to acid and bile salts has also been related to de-
regulation of microRNAs (miRNA),57,58 a class of short noncod-
ing RNA involved in a variety of cellular processes. In particular 
miRNA-145 was linked to the activation of BMP4 pathway,59 
which has been previously implicated in the development of BE 
through the activation of the Hedgehog pathway.60 BE and EAC 
present a distinct miRNA expression profile,61,62 which could be 
potentially useful for diagnostic purposes due to the fact that 
miRNAs are stable and detectable in blood.63
Another class of noncoding RNA, long noncoding RNA (ln-
cRNA), which have diverse cellular properties including gene 
regulation and control of cell growth and migration,64 has re-
cently also been implicated in Barrett’s carcinogenesis. Wu and 
collaborators65 showed that the lncRNA AFAP1-AS1 is hypo-
methylated and overexpressed in BE and EAC and its silencing 
in vitro inhibited invasion and promoted apoptosis.
CLINICAL PREDICTORS OF CANCER RISK 
Until recently the only clinical factor with practical implica-
tions in the management of BE was the histological diagnosis 
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of dysplasia. The two largest population studies in the Northern 
Irish and Danish cohorts confirmed that the cancer risk in pa-
tients with low grade dysplasia (LGD) is approximately 5 times 
higher than nondysplastic patients.8,10 It is standard practice to 
monitor patient with LGD at closer intervals. Unfortunately a 
histopathological diagnosis of dysplasia is often associated to a 
high degree of interobserver variability even among expert GI 
pathologists, hence doubts have been shed on the exact clinical 
usefulness of this marker for patient stratification.66,67 There are 
additional clinical factors that have been shown to influence the 
risk of progression of BE to cancer. These clinical elements have 
the potential to inform the physician about the surveillance and 
management of patients with BE. Several studies have shown 
that increasing BE length is associated with higher risk of pro-
gression to high grade dysplasia (HGD) and malignancy.8,9,68-70 
The most common cutoff used in the literature for the definition 
of long segment of BE is 3 cm or more; however there is high 
variability in the literature in the cutoffs used. Overall it is justi-
fied to consider long segment of BE at higher risk. The 2013 
British Society of Gastroenterology (BSG) guidelines for the 
management of BE recommend to tailor surveillance interval on 
basis of the length of the BE.3
The large Northern Irish population study has also found that 
the presence of intestinal metaplasia (IM) was associated with a 
hazard ratio for progression to cancer of 3.54 (95% CI, 2.09 to 
6.00).8 However, the issue of whether IM confers increased can-
cer risk conceptually applies only to countries, such as United 
Kingdom, where IM is not required for a diagnosis of BE.2,3
Visible endoscopic lesions including ulcers are also associated 
with a high risk of HGD and early cancer and warrant close 
monitoring,71 but it must be recognized that the absence of dys-
plasia in the presence of visible lesions is often due to sampling 
error. Overall, it is clear that there is a paucity of clinical factors 
which can inform the physician about individual cancer risk 
and those that are currently used are affected by a significant 
degree of subjectivity either in the diagnosis, i.e., dysplasia, or 
in the definition, i.e., length. Hence there is the need for more 
objective risk stratification tools to inform patient management. 
MOLECULAR BIOMARKERS
Molecular biomarkers have been investigated over the last 20 
years in the field of BE with the aim of providing the physician 
with predictors of disease behaviour and hence aiding clinical 
management. The advantage of biomarkers over the current 
standard, i.e., dysplasia, relies on the possibility to provide an 
objective measure of the molecular changes in tissue, which 
are known to correlate with progression of disease. In addition, 
since molecular abnormalities can extend within the BE over 
larger epithelial surface than cellular dysplasia, they could be 
Fig. 2. Patient with Barrett’s esopha-
gus, with positivity at three different 
biomarkers. (A) Flow-cytometric 
analysis of nuclear DNA content. 
The aneuploidy peaks (AnG1 and 
AnG2) can be clearly identified as 
separate from the normal G1 and 
G2 peaks. (B) Overexpression of p53 
detected by immunohistochemistry 
(×10). (C) Immunohistochemistry 
staining for cyclin A shows positive 
cells on the surface of the epithelium 
(insets, ×40). Positive cells in deep 
glands are considered within the 
normal limit.
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less subject to sampling error.72
Gain or more rarely loss of individual chromosomes (aneu-
ploidy) or duplication of the entire genome (tetraploidy) are 
common events in EAC and can precede the development of 
cancer or even dysplasia (Fig. 2A).73 Gross abnormalities in the 
DNA content are tumorigenic since these can lead to altered 
expression of cancer-related genes. In particular loss of hetero-
zygosity at tumor suppressor genes, such as p16 and p53, have 
been linked to acquisition of dysplasia in BE.74,75 Reid and col-
laborators76 have contributed significantly to the understanding 
of the timing and distribution of these molecular changes and 
have conducted large retrospective studies on prospectively col-
lected samples to evaluate the usefulness of these biomarkers as 
cancer predictors. For example they have showed that among 
patients with nondysplastic BE or at most LGD, those without 
aneuploidy had a 0% 5-year cumulative cancer incidence com-
pared with 28% for those with aneuploidy. In another study, the 
prevalence of 17p (p53) loss of heterozygosity (LOH) at baseline 
increased from 6% in nondysplastic patients to 57% in patients 
with HGD. Using baseline 17p (p53) LOH as a predictor of pro-
gression in 325 patients with BE, those with this marker had 
increased risk of HGD and cancer with a relative risk (RR) of 3.6 
(95% CI, 1.3 to 10) and 16 (95% CI, 6.2 to 39), respectively.77 
In a follow-up study three biomarkers (abnormal DNA content, 
p53 LOH, and p16 LOH) were evaluated as a panel in a cohort of 
243 patients, and a step-wise increase in the cancer progression 
risk was found with increasing number of positive biomarkers. 
This showed a RR for cancer of 38.7 (95% CI, 10.8 to 138.5) at 
10 years of follow up when all three biomarkers were positive.78 
The main limitation of these studies was that assessment of an-
euploidy was performed with a complex methodology involving 
flow-cytometric analysis on snap-frozen biopsies. However, it is 
now possible to assess aneuploidy with alternative techniques, 
which are potentially more applicable to clinical setting. One of 
them is image cytometry (IC), which can be performed on thick 
sections from paraffin-embedded specimens. IC was showed to 
be comparable to flow-cytometry for the assessment of aneu-
ploidy in BE tissue.79 A retrospective case-control study con-
firmed that a panel consisting of LGD and two molecular bio-
markers (aneuploidy by IC and immunohistochemistry [IHC] for 
Aspergillus oryzae lectin) effectively separated progressors from 
nonprogressors.80 Each individual positive marker was associ-
ated with an OR of 3.74 (95% CI, 2.43 to 5.79) for progression 
to HGD/EAC. An alternative method for assessment of aneu-
ploidy is fluorescent in situ hybridization (FISH), which employs 
fluorescent probes to target specific DNA sequences. FISH has 
been studied in BE in combination with cytological brushings, 
which has the advantage over biopsies to sample larger epithe-
lial areas. In particular it was found that FISH for chromosome 
7 and 17 was more accurate that IC for detection of aneuploidy 
on cytological preparations and could detect HGD/EAC with 
a sensitivity and a specificity of 85% and 84%, respectively.81 
The same group used FISH to detect copy changes of cancer-
related genes, such as c-myc, EGFR, and 20q13 locus, which 
were found to be amplified in up to 14% and 50% of cases with 
HGD and EAC, respectively.82 Similarly, a different group of au-
thors found that FISH for four cancer-related loci (c-myc, HER2, 
20q13, and p16) on brushing samples had better accuracy than 
conventional cytology or IC on brushings for the diagnosis of 
dysplasia.83 A case-control study with FISH markers is currently 
being undertaken to predict disease progression in a Dutch co-
hort of patients with BE. 
Mutation in the tumor suppressor gene p53 is the most recur-
rent genetic hit in EAC.84 p53 function is associated with G1 ar-
rest during cell cycle and apoptosis; as a result, mutation of the 
p53 gene will adversely affect control of cell proliferation and 
impair activation of apoptosis, promoting carcinogenesis.52,85 
Mutation of p53 leads to either stabilization of an inactive prod-
uct or complete absence of the protein. Both events can be effi-
ciently detected by IHC, which is a cost-effective test applicable 
to clinical setting (Fig. 2B).86 A case-control study by Murray 
and coworkers87 found that abnormal p53 protein expression 
was associated with progression to EAC at follow-up, with an 
OR of 11.7 (95% CI, 1.93 to 71.7). It was proposed that p53 
expression can be used as biomarker of malignant expression 
in BE, however due to the low sensitivity it was also suggested 
that additional biomarkers would have needed as adjunct. These 
results have been confirmed in a more recent and larger case 
controlled study on 720 patients with BE, where p53 protein ex-
pression was associated with an increased risk of neoplastic pro-
gression (RR, 5.6; 95% CI, 3.1 to 10.3) and proved to be a more 
powerful predictor of neoplastic progression than histological 
diagnosis of LGD.88 p53 IHC has also been shown to be a useful 
adjunct to the histopathological diagnosis of dysplasia, assisting 
the pathologist in interpreting less straightforward pathological 
patterns.89 In keeping with this, the 2013 BSG guidelines recom-
mend the use of p53 IHC as adjunct to conventional histopa-
thology.3
Promoter hypermethylation can lead to silencing of gene ex-
pression and cancer and has been shown to be associated with 
widespread epigenetic changes involving global DNA hypo-
methylation and targeted hypermethylation of tumor suppressor 
genes.90 Kaz and collaborators91 used a microarray-based ap-
proach on 96 esophageal samples to determine the methylation 
profiles of normal esophagus, nondysplastic BE, BE with HGD 
and EAC, and they found increasing methylation levels at gene 
promoters along the pathological progression. Hence, similarly 
to p53, methylation markers could represent a useful adjunct 
to histopathology. In a different study, a four-gene (SLC22A18, 
PIGR, GJA12, and RIN2) methylation panel was found to strat-
ify patients with different stages of BE into three risk groups 
based on the number of genes methylated, with potential clini-
cal utility (low risk: <2 genes, intermediate: 2, and high: >2).92
Hypermethylation of p16 and APC was also found to associ-
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ate with dysplasia at a biopsy level and correlate with cancer 
risk at a patient level, with an OR for combined HGD/EAC of 
14.97 (95% CI, 1.7-inf) when both genes were methylated.93 In 
a different study methylation of 10 genes (HPP1, RUNX3, RIZ1, 
CRBP1, 3-OST-2, APC, TIMP3, p16, MGMT, p14) were analysed 
in a large cohort of EAC cases (n=77), BE (n=93), and normal 
esophageal specimens (n=64). Three of them, p16, RUNX3, and 
HPP1, showed the most significant hypermethylation levels in 
cancer and in a case control cohort were associated with the 
risk of histological progression of BE to cancer at 2-year follow-
up with an OR of 1.74 (95% CI, 1.33 to 2.2), 1.8 (95% CI, 1.08 to 
2.81), and 1.77 (95% CI, 1.06 to 2.81), respectively.94
Cyclin A is a protein that is involved in the regulation of pro-
gression through the cell cycle. In normal columnar gastrointes-
tinal tissue, including nondysplastic BE, the expression of cyclin 
A is confined to the base of the crypts. With increasing grades 
of dysplasia, the expression of cyclin A moves towards the up-
per third of the crypts and the surface epithelium (Fig. 2C). In 
a study including 16 cases of BE that progressed to cancer and 
twice as many nonprogressor controls, surface expression of 
cyclin A correlated with the risk of progression with an OR for 
cancer of 7.5 (95% CI, 1.8 to 30.7).95
Despite the large number of molecular biomarkers studied, 
there is generally a lack of large prospective studies that have 
validated these and this has made introduction into clinical 
practice problematic. The biomarker with the largest data avail-
able is p53 IHC, which, due to the ample validation in indepen-
dent cohorts and simplicity of the methodology, is likely closer 
than other biomarkers to clinical application. Aneuploidy is also 
very promising, but validation with the use of cost-effective 
techniques is needed to make it compatible with a clinical set-
ting.
GUIDELINES
There are recent guidelines on screening and management 
of patients with BE. This review will focus on those published 
in the last 3 years, as these have taken into account the most 
recent data on epidemiological aspects of BE.2,3,96 Recent data 
have not provided strong evidence to support screening pro-
grams. The American Society of Gastrointestinal Endoscopy 
(ASGE) guidelines concluded that endoscopic screening for BE 
is controversial due to lack of randomized controlled trials (RCT), 
hence it cannot be recommended.96 On the other hand, the 
American Gastroenterology Association (AGA) states that the 
practice of screening in the United States remains widespread 
among physicians. The current AGA guidelines suggest that 
patients with multiple risk factors associated with BE and EAC 
should be screened. Risk factors were defined as age 50 years or 
older, male sex, white race, chronic GERD, hiatus hernia, elevat-
ed body mass index, and intra-abdominal distribution of body 
fat, but the threshold of risk factors that should trigger interven-
tion remained undefined.2 This recommendation is in agreement 
with that issued by the BSG, which however is more practical 
with concern to the definition of the population at risk when 
considering multiple risk factors. These guidelines state that 
endoscopic screening should be taken into account in a selected 
population with gastroesophageal reflux symptoms and multiple 
risk factors (at least three of age 50 years or older, white race, 
male sex, obesity).3 It is also advised that for individuals with a 
positive family history of BE and EAC the threshold for screen-
ing should be lowered. The issue of whether screening should 
focus on individuals with reflux symptoms remains unresolved. 
The AGA working group decided that screening should not be 
directed only to individuals with reflux, as this is extremely 
common in the general population,21 yet approximately 40% 
of patients with EAC do not report a symptomatic history of 
gastroesophageal reflux.97 On the other hand, GERD is the 
strongest risk factor for BE and EAC, and included as generic 
risk factor among other may result in justifying screening in a 
large population of individual (e.g., every white male over 50 
years of age), with significant burden on the health care system. 
Clearly there is a need to tailor recommendations for screening 
interventions in order to target the largest proportion of patients 
with prevalent disease, without exposing an unjustified number 
of individuals to procedures which may generate psychologi-
cal morbidity, reduce the quality of life and increase insurance 
premiums in places where health provision is mainly insurance 
based. In addition, screening performed with conventional 
endoscopy and tissue biopsies is expensive and would have 
significant bearing on the health care budget. Hence there is a 
need for less invasive and cost-effective devices for BE screen-
ing, ideally applicable to primary care. Non-endoscopic cell 
collection devices like the CytospongeTM, office-based transnasal 
esophagoscopy and tethered or untethered capsule endoscopy 
are the most promising tools but more studies are required to 
make conclusions regarding their diagnostic accuracy and feasi-
bility on a larger scale.22
Surveillance in BE is also a controversial issue. While it is 
generally accepted that patients with BE should be monitored 
over time, definitive evidence that systematic endoscopic sur-
veillance improves survival is still lacking. Several retrospective 
studies have showed that EAC and junctional adenocarcinomas 
diagnosed within a previous background of known BE have an 
earlier stage and improved survival compared to cancers pre-
senting de novo.98-100 However these studies are limited by lead 
time bias. By contrast, a more recent case-control study from 
Corley and collaborators101 has suggested that previous endo-
scopic surveillance has no significant impact on mortality from 
EAC. The authors, however, found an unusually high prevalence 
of advanced stage cancers in patients undergoing surveillance, 
suggesting that in this cohort of patients endoscopic surveil-
lance did not efficiently achieve the expected goal of detecting 
early disease. Also in this study, there was a higher proportion 
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of dysplasia in previous biopsies of cases that died of EAC com-
pared to controls that did not die of this disease. Hence, there 
may be methodological problems with surveillance protocols in 
routine practice outside of specialist centers.
Nevertheless the practice of surveillance is generally accepted 
and recommended by all gastroenterology societies; the AGA 
working group indeed commented on the fact that it remains 
unclear whether endoscopic surveillance is beneficial, hence it 
was not possible to make meaningful recommendations regard-
ing the optimal intervals between endoscopic procedures.102
The surveillance programs recommended by the BSG, the 
ASGE, and the AGA are summarized in Table 1. Overall, while 
we wait for convincing evidence that endoscopic surveillance is 
beneficial, in view of the well-established association between 
BE and EAC and the very poor outcomes from this cancer, it 
seems clinically sensible to survey BE patients over time. A 
multicenter U.K. based RCT (BOSS trial) is currently being un-
dertaken to address the long-term clinical impact of endoscopic 
surveillance.103 In this study, patients with BE without dysplasia 
are being randomized into surveillance versus no surveillance 
(with OGD on demand if needed). This will hopefully provide 
scientific evidence to support the practice of endoscopic surveil-
lance. 
One of the main implications of widespread surveillance is 
that the current gold standard is endoscopy with biopsies, which 
is invasive and expensive. Research is focusing currently on 
two directions to improve cost-effectiveness of surveillance. As 
discussed above, one is the development of biomarkers to risk 
stratify patients into low and high risk individuals. The ratio-
nale is to provide a more objective assessment of the individual 
cancer risk to overcome the shortfalls of a pathological assess-
ment of dysplasia. This would allow stretching out intervals for 
surveillance in low risk patients with the potential to discharge 
them and on the other hand anticipate ablation treatment in 
high risk patients. The second research goal is to devise a less 
invasive and more cost-effective technologies for surveillance. 
Differently from screening devices, those applicable to surveil-
lance setting would need some form of tissue collection either 
for pathological analysis or biomarker assessment. 
Currently little progress has been made with regards to che-
moprevention, and this remains a key area for investigation. 
There are retrospective data that suggest that proton pump in-
hibitors (PPI) correlate with decreased risk of HGD and EAC,104 
but definitive proof is lacking due to difficulties in designing 
RCTs with a placebo arm. The only drug that has made its way 
to an RCT is aspirin (AspECT study). Aspirin inhibits cyclo-
oxygenase 1 and 2 (COX-1 and COX-2), regulator enzymes 
of prostaglandin E2 production, which has been shown to be 
involved in angiogenesis and invasiveness in EAC and other GI 
malignancy.105-107 The results of the AspECT study are awaited 
Table 1. Comparison of Surveillance Recommendations in Recently Published Guidelines
BSG (2013) ASGE (2012) AGA (2011)
Nondysplastic BE
   Length of BE taken into consideration Yes No No
   Gastric metaplasia compatible with BE diagnosis Yes No No
   Repeat OGD in <3 cm
3–5 yr*
≥3 cm
2–3 yr
3–5 yr 3–5 yr
Indefinite for dysplasia
   Acid suppression advised Yes Yes No recommendation made
   Repeat OGD advised Yes
In 6 mo†
Yes
No specific time frame
Low grade dysplasia
   Initially repeat OGD in 6 mo   6 mo 6–12 mo
   Surveillance OGD every 6 mo 12 mo 6–12 mo
High grade dysplasia
   Plan MDT discussion with the 
view to perform endoscopic 
therapy with RFA+/- EMR‡
Endoscopic therapy with 
RFA+/- EMR to be preferred 
to surgery and endoscopic 
surveillance‡
Endoscopic therapy with 
RFA+/- EMR
Surgery and 3-monthly surveil-
lance in alternative‡
BSG, British Society of Gastroenterology; ASGE, American Society for Gastrointestinal Endoscopy; AGA, American Gastroenterological Associa-
tion; BE, Barrett’s esophagus; OGD, osophagogastroduodenoscopy; MDT, multi-disciplinary team; RFA, radiofrequency ablation; EMR, endoscopic 
mucosal resection.
*Discharge recommended in case of short segment of BE (<3 cm) without intestinal metaplasia; †If no definite dysplasia found in 6 months, pa-
tient should be regarded as nondysplastic; ‡RFA seems the ablative technique with the best safety and efficacy profile.
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to conclude whether Aspirin in combination to PPI can be part 
of the management algorithm of patients with BE. Since this 
trial is also randomizing patients between two different doses of 
esomeprazole, some information on the chemopreventive effect 
of PPI will transpire. 
ADVANCED ENDOSCOPIC IMAGING TO IDENTIFY HIGH 
RISK PATIENTS
There has been a great deal of research over the last years in 
an attempt to develop novel endoscopic techniques to enhance 
detection of inconspicuous dysplasia (Table 2). This would have 
the potential advantage to enable biopsies to be targeted to-
wards areas containing histological dysplasia and eliminate the 
need of multiple random sampling. The benefit would be two-
fold: 1) better cost-effectiveness due to shorter endoscopies and 
reduced work-load for the pathologist; and 2) improved patient 
tolerance. Three main fields have been explored so far; i.e., dye 
chromoendoscopy, light filtering, and electronic image repro-
cessing.
Chromoendoscopy is a technique by which a chemical agent 
is sprayed on the Barrett’s mucosa in an attempt to enhance 
the detection of dysplasia. Several different agents have been 
studied including methylene blue (MB), Lugol’s solution, indigo 
carmine (IC), and acetic acid (AA). MB is a vital agent that is 
avidly incorporated by cells with intestinal differentiation and 
has been the first dye investigated in the field of BE. There are 
conflicting results on the utility of MB in dysplasia detection. 
A recent meta-analysis by Ngamruengphong et al. concluded 
that MB does not provide a clinical advantage compared to the 
Seattle protocol (random quadrantic biopsies every 2 cm).108
IC is a contrast agent which helps highlight areas of subtle 
mucosal irregularity which are otherwise very difficult to iden-
tify on conventional white light endoscopy. IC has been studied 
by Kara and collaborators109 in a small randomized crossover 
study, which compared high resolution endoscopy (HRE), IC 
chromoendoscopy and narrow band imaging (NBI). In this 
study, HRE had equal yield of dysplasia compared to advanced 
imaging techniques. 
AA at the concentration of 2% to 3% is an inexpensive and 
safe imaging adjunct that when in contact with surface epithe-
lium causes protein denaturation and induces a typical whit-
ening effect on BE mucosa. Increased vascularisation of areas 
of early neoplasia results in enhanced and rapid loss of aceto-
whitening, which appears as area of redness on a white back-
ground. Despite two early randomized studies which failed to 
show increased detection rate of dysplasia by AA chromoendos-
copy,110,111 a more recent large single-center retrospective study 
has found a higher histological yield in patients which received 
AA enhanced chromoendoscopy.112 More studies are needed to 
ascertain whether AA is a useful adjunct for dysplasia detection. 
NBI is based on optical filters controlled by a button switch, 
which allows one to isolate narrow wave-lengths corresponding 
to the green and blue spectra of light. In the blue-green range 
light has reduced penetration into tissues and therefore this 
helps visualization of superficial vessels and mucosal pits.113 NBI 
can be less time consuming and easier to perform in compari-
son to white light endoscopy, but it is still subject to interob-
Table 2. Comparison of Imaging Techniques Investigated to Increase Detection Rate of Dysplasia in Barrett’s Esophagus
Technique Advantages Disadvantages
Methylene blue chromoendoscopy Cheap 
Widely available
Conflicting data 
Concerns about DNA toxicity
Indigo carmine chromoendoscopy Cheap 
Widely available
Comparable to high resolution endoscopy
Acetic acid chromoendoscopy Cheap 
Widely available
Conflicting data
Validation required
Narrow band imaging Widely available
Endoscope integrated
Conflicting data
Narrow field if combined to magnification
Autofluorescence imaging Endoscope integrated
Easy read out
Wide field of view
Conflicting data
High false positive rate         
Not widely available 
Confocal laser endomicroscopy Real time histology    
Compatible with other red flag techniques
Narrow field of view     
Costs
Intravenous dye required
Optical coherence tomography Real time readout of histological patterns
Wide field of view
Preliminary data only
Complex readout of imaging patterns
Costs
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server variability. In a prospective study with a tandem design, 
Wolfsen and collaborators114 found that NBI was superior to 
standard-resolution white light endoscopy with random biopsies 
for the detection of higher grades of dysplasia. A more recent 
multicenter randomized crossover study which compared NBI 
with high-resolution white light endoscopy only found a higher 
histological yield on the per-location analysis but not in the 
per-patient analysis, suggesting that the clinical overall value of 
NBI may be limited.115 NBI however required fewer biopsies per 
patient compared with the standard approach, which may lead 
to cost savings.
A meta-analysis by Mannath et al.116 included 446 patients 
with 2,194 lesions and they reported that NBI with magnifica-
tion shows high diagnostic precision in detecting high-grade 
dysplasia, with a sensitivity of 96% and specificity 94%. 
Autofluorescence imaging (AFI) utilizes high frequency blue 
light, which has the property to excite endogenous fluorophores 
to emit green fluorescence. In the presence of BE with early 
neoplasia, architectural and molecular changes in the columnar 
mucosa lead to reduction of green fluorescence. Dysplastic le-
sions therefore can be flagged-up as purple-red areas on a green 
background. Despite early enthusiasm for the utility of AFI in 
dysplasia detection,117-119 two crossover studies and a recent 
analysis of available clinical trials have showed a very limited 
diagnostic value in this technology for BE endoscopic surveil-
lance.120,121 This is partly due to the high false positive rate of 
AFI, which in some studies has reached 80%. The significance 
of this false positivity is not yet clear. A multicenter study has 
been conducted by our institution with European collaborators, 
where biopsies directed by AFI were processed for a large panel 
of molecular biomarkers and the outcome of the biomarker 
analysis was compared with that of the Seattle protocol. This 
study found that AFI positivity correlated with molecular ab-
normalities of the Barrett’s tissue and even if that area was not 
dysplastic on a focal biopsy there was a very high correlation 
between the molecular read-out from these areas and the over-
all dysplasia status of the patient.122 In the per-patient analysis, 
a small panel of three biomarkers (p53 IHC, cyclin A, and an-
euploidy) assessed on AFI positive areas had equal diagnostic 
accuracy to the Seattle protocol. AFI could therefore be a useful 
tool to direct biopsies for the detection of biomarkers and hence 
more objectively determine the risk status of the patient. In the 
future the combination of advanced imaging and molecular 
biomarkers could represent an improved strategy for improved 
stratification of BE patients.123
Other imaging technologies include confocal laser endomi-
croscopy, optical coherence tomography, diffuse reflectance 
spectroscopy and light scattering spectroscopy. 
Confocal laser endomicroscopy (CLE) allows for high resolu-
tion assessment of the mucosa using endoscopically delivered 
laser light with magnification beyond ×1,000 allowing for im-
aging of cellular and subcellular structures and capillaries.124 An 
international multicenter, prospective, randomized, controlled 
trial by Sharma et al.125 showed that probe-based CLE used as 
part of a multimodal imaging approach in combination with 
high-definition white-light endoscopy (HD-WLE) and NBI im-
proved the sensitivity for dysplasia detection compared with 
HD-WLE alone. Another RCT on 192 patients compared HD-
WLE with Seattle protocol versus HD-WLE plus endoscope-
integrated CLE (eCLE) and targeted biopsies.126 This study found 
that the addition of eCLE increased the diagnostic yield for neo-
plasia from 6% to 22%, with a 4.8-fold reduction in the number 
of total biopsies required. However, the main issue of CLE is the 
narrow field of view and the best flagging technique to direct 
the operator as to which regions to analyse with the CLE probe 
remains to be established.
Optical coherence tomography (OCT) relies on the backscat-
tering of light to obtain cross-sectional images of the tissue. It 
enhances the endoscopic image of the superficial layers of the 
esophagus. The technique is similar to endosonography, but 
the image formation in OCT depends on variations in the re-
flectance of light from different tissue layers. OCT imaging has 
demonstrated anatomic structures such as crypts and glands 
that could potentially permit endoscopists’ to diagnose mucosal 
abnormalities such as BE, including dysplastic changes.127,128
Intrinsic fluorescence, reflectance, and light-scattering spec-
troscopy provide complementary data on biochemical and 
morphologic changes that occur during the development of 
dysplasia.129,130 However convincing data are still lacking on the 
clinical applicability of these techniques, neither as single mo-
dality or in combination.131
In conclusion, currently there is insufficient evidence to rec-
ommend advanced imaging modalities for routine Barrett’s sur-
veillance. High-resolution endoscopy should be the minimum 
standard and the addition of more complex imaging modalities 
should be reserved to tertiary referral centers with a high vol-
ume of dysplastic cases. In the future multi-modal imaging, in 
combination with molecular information has the potential to 
overcome many of the limitations of the current clinical stan-
dard. 
CONCLUSIONS AND FUTURE PERSPECTIVE
It is now increasingly clear that BE is a multifactorial disease, 
where a genetic predisposition interacts with the environment. 
Only very recently GWAS studies have started to provide the 
first insights into the genetic variants that predispose to the 
development of BE and EAC, but we are still far from being 
able to draw a risk profile based on the inherited genetic fac-
tors. Since there are multiple risk loci, each conferring a low in-
creased risk, it may be difficult to make a clinical-risk tool from 
this information. In the absence of practical ways to identify in-
dividuals at high risk based on their genetic profile, for the time 
being it seems logical to look for clinical risk factor. Presently, 
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clinical factors, such as reflux symptoms, age >50 years, white 
race, male sex and obesity, are the key elements that trigger 
referral for endoscopic screening. However, there is uncertainty 
about how many factors should be present to define a high risk 
population. For example, reflux is regarded as the strongest 
risk factor for BE; however, more than 1/3 of patients with EAC 
deny previous history of heartburn and the prevalence of BE 
among reflux sufferers is only about 10%. Hence, the popula-
tion that needs to be screened to diagnose enough cases of BE 
or cancer to impact on the overall mortality, is very large. As a 
consequence, it is mandatory to identify a minimally invasive 
screening test, with low cost and wide applicability to primary 
care. This is a very relevant area for future research.
The current surveillance algorithm heavily relies on the his-
tological assessment of dysplasia based on random biopsies. It 
is still debated whether endoscopic surveillance is an effective 
measure to improve survival in patients with BE, due to con-
troversial published data. This likely depends on the fact that 
dysplasia is difficult to detect endoscopically, as well as the fact 
that endoscopists adhere poorly to recommended protocols and 
pathologist struggle to agree on the diagnosis of dysplasia.66,67,132 
Flagging endoscopic techniques have been investigated to 
inform biopsy sampling, however up to now single modali-
ties have not been proven to be superior to the current gold 
standard. A multimodal approach might represent an attractive 
possibility which has not been intensively studied so far. Mean-
while, the minimum standard seems to be high-resolution en-
doscopy, allowing for sufficient time for careful inspection and 
targeted biopsies on suspicious mucosal areas.3,133
Controversial data have been published on the cancer risk 
associated with a diagnosis of dysplasia, likely due to high in-
terobserver variability and possibly also a different threshold 
used for the diagnosis of dysplasia in different countries or 
practices.66,67 More objective measures of cancer risk are needed 
to inform clinical decisions. Biomarkers are natural candidates 
as molecular changes not only correlate with dysplasia, but 
can precede it and are often more objective. Even though sev-
eral biomarkers have been showed to correlate with prevalent 
dysplasia and cancer risk, it is clear that panels of biomarkers 
provide the most accurate measure.78,80 Biomarkers need to be 
cheap, easy to interpret and applicable to the clinical setting. 
p53 IHC is an example of such biomarker, which couple low 
costs with good clinical performance. More studies within pro-
spective case-control cohort are needed to validate existing and 
novel biomarkers. The emerging sequencing technology needs 
also to be explored as it is becoming increasingly affordable 
and can provide large scale information potentially able to un-
cover unexplored areas of the genome associated with cancer 
risk. Multicenter studies are the ideal setting to test biomarkers 
in order to provide large enough cohorts of patients to achieve 
meaningful conclusions. 
In the future, it is possible to envisage a scenario where in-
expensive and minimally invasive screening techniques will 
help diagnose a large proportion of unknown BE. Coupled with 
the objective assessment of an individual’s risk for cancer, this 
will allow tailoring patient management with choosing between 
early ablation in high risk BE (nondysplastic with aberrant mo-
lecular profile as well as frankly dysplastic cases) and prolonged 
endoscopic surveillance intervals or monitoring with minimally 
invasive devices in patients with low risk BE. 
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